Skip to main content

Roche's event on key data presented at the MDA Virtual Clinical & Scientific Conference 2021

Roche has hosted a virtual event on Friday, 19th March 2021

agenda
Agenda:
Phase II/III SUNFISH part 2: 24-month efficacy and safety of risdiplam in patients with Type 2 or non-ambulant Type 3 spinal muscular atrophyPaulo Fontoura, M.D. Ph.D., Global Head Neuroscience and Rare Diseases Clinical Development
Roche Neuroscience and Rare Disease franchise updateSimona Skerjanec, Therapeutic Area Head Neuroscience and Rare Diseases, Global Product Strategy
Q&AKarl Mahler, Head of Investor Relations and Roche Group Planning

Webinar Replay

InvestorsPast IR Events
View more Events

Downloads

Download Presentation

PDF

Related links

  • Roche’s Annual Report 2020

    Investors

    How medicines are making an impact in the lives of patients

  • Governance

    About Roche

    Our corporate governance principles focus on sustainable value creation and promote a culture that recognises standards of good corporate governance and a commitment to transparent communication.

  • Product Development Pipeline

    Solutions

    Discover our pipeline of Pharmaceutical and Diagnostics developments

  • Frequently asked questions

    Investors

    We answer the Roche investors-related most frequently asked questions